XNAS · Healthcare · Biotechnology
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | Q1 2026 | -0.89 | -0.96 | -7.87% | $0 | ❌ Miss | +0.12% | -6.82% | — |
| 2026-03-05 | Q4 2025 | -0.86 | -0.78 | +9.30% | $0 | ✅ Beat | -2.97% | -4.57% | -1.43% |
| 2025-11-10 |
| Q3 2025 |
| -0.78 |
| -0.83 |
| -6.41% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-11 | Q2 2025 | -0.71 | -0.90 | -26.76% | $0 | ❌ Miss | +1.33% | +10.64% | +8.51% |
| 2025-03-03 | Q4 2024 | -1.10 | -0.61 | +44.55% | $0 | ✅ Beat | -0.34% | -1.36% | -18.29% |
| 2024-11-13 | Q3 2024 | -0.82 | -0.61 | +25.61% | $0 | ✅ Beat | -11.86% | -13.97% | -16.13% |
| 2024-08-14 | Q2 2024 | -0.54 | -0.65 | -20.37% | $0 | ❌ Miss | -0.38% | -0.13% | -0.79% |
| 2024-05-08 | Q1 2024 | -1.05 | -0.70 | +33.33% | $0 | ✅ Beat | +3.63% | +12.33% | +6.85% |
Showing last 8 quarters.